Evidence map›Paper›PMID 40738247›Full record

Trial reportPractical radiation oncology

Volumetric Changes and Acute Toxicity With

Vishal R Dhere, David M Schuster, Subir Goyal, Eduard Schreibmann, Nikhil T Sebastian, Sagar A Patel, Sheela Hanasoge, Joseph W Shelton, Pretesh R Patel, Bruce W Hershatter and 3 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Practical radiation oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. [European urology · 2026
    Trial
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Vishal R DhereDepartment of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia. Electronic address: vdhere@emory.edu.
David M SchusterDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia.
Subir GoyalBiostatistics Shared Resource, Winship Cancer Institute of Emory University, Atlanta, Georgia.
Eduard SchreibmannDepartment of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia.
Nikhil T SebastianDepartment of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia.
Sagar A PatelDepartment of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia.
Sheela HanasogeDepartment of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia.
Joseph W SheltonDepartment of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia.
Pretesh R PatelDepartment of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia.
Bruce W HershatterDepartment of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia.
Olayinka A Abiodun-OjoDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia.
Ismaheel O LawalDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia.
Ashesh B JaniDepartment of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia.

Funding

Winship Cancer Institute Cancer Center Support GrantP30CA138292 · NCI · EMORY UNIVERSITY · PI Suresh S Ramalingam · 2009 to 2026
$47.5M
Advanced PET-CT Directed Post-Prostatectomy Radiotherapy to Enhance Prostate Cancer OutcomesR01CA226992 · NCI · EMORY UNIVERSITY · PI JANI, ASHESH, SCHUSTER, DAVID MICHAEL · 2019 to 2023
$3.1M
NCI NIH HHS P30 CA138292NCI NIH HHS R01 CA226992
6 · The paper itself

Abstract

purposeWe evaluated changes in radiation therapy target volume and acute toxicity using METHODS AND MATERIALS: We performed an institutional review board-approved, randomized trial comparing fluciclovine (Arm 1) and PSMA (Arm 2)-guided postprostatectomy radiation therapy in patients with detectable prostate-specific antigen after prostatectomy. Treatment volumes were rigidly defined based on PET, and simultaneous integrated boosts to PET uptake in the prostate bed (70.2-76.0 Gy) or pelvis (54.0-56.0 Gy) were allowed. Clinical target volumes (CTVs) included: prostate bed (CTV

resultsIn total, 140 patients were enrolled with 70 randomized to each arm; 11 Arm 1 and 10 Arm 2 patients did not receive radiation on study and were excluded. Fluciclovine and PSMA incorporation increased both CTV

conclusionsAlthough both PSMA and fluciclovine use modestly increased target volumes, significantly more fluciclovine patients received prostate bed boosts. Planning directives were met for most patients, and acute toxicity was mild in both Arms. Analysis of biochemical control, late toxicity, and patient-reported outcomes are forthcoming.

Indexed as

Carboxylic AcidsCyclobutanesPositron Emission Tomography Computed TomographyProstatic NeoplasmsRadiotherapy, Image-GuidedAgedGallium IsotopesGallium RadioisotopesHumansMaleMiddle AgedProstatectomyRadiotherapy Planning, Computer-AssistedCarboxylic AcidsCyclobutanesfluciclovine F-18Gallium IsotopesGallium Radioisotopes

Identifiers

PMID40738247
PMCPMC12447277

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.